(Q34942505)

5 August 2017

1 reference

title

The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus (English)

1 reference

5 August 2017

0 references

1 reference

1 reference

Joseph Torresi

1

1 reference

5 August 2017

1 August 2002

1 reference

Journal of Clinical Virology

5 August 2017

1 reference

5 August 2017

25

1 reference

5 August 2017

97-106

1 reference

5 August 2017

2

1 reference

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Hepatitis B virus. The major etiology of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Mutational analysis of the fingers and palm subdomains of human immunodeficiency virus type-1 (HIV-1) reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Analysis of mutations at positions 115 and 116 in the dNTP binding site of HIV-1 reverse transcriptase.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Vaccine-induced escape mutant of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

The clinical significance of surface antigen variants of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

HBsAG positive reactivity in man not due to hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

RNA virus mutations and fitness for survival

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Increased polymerase fidelity of E89G, a nucleoside analog-resistant variant of human immunodeficiency virus type 1 reverse transcriptase.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Production and immunological analysis of recombinant hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Persistent infection of humans with hepatitis B virus: mechanisms and consequences.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Expression of hepatitis B virus surface antigen in yeast

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Hepatitis B surface antigen (HBsAg) subtype-specific antibodies in persons vaccinated against hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Prolonged immunity after late booster doses of hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

A novel hepatitis B virus variant in the sera of immunized children

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Long-term therapy of chronic hepatitis B with lamivudine.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Susceptibility to hepatitis B despite high titre anti-HBs antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

A prospective study on the development of hepatocellular carcinoma from liver cirrhosis with persistent hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Molecular epidemiology of hepatitis B virus vaccine variants in Singapore

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Immunogenicity of recombinant hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Mutational analysis of HBsAg assembly

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Synthesis and assembly of hepatitis B virus surface antigen particles in yeast

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Infant and adolescent hepatitis B immunization up to 1999: a global overview

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Identification and transmission of hepatitis B virus-related variants

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Loss of the common "A" determinant of hepatitis B surface antigen by a vaccine-induced escape mutant

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Predictions of the emergence of vaccine-resistant hepatitis B in The Gambia using a mathematical model

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2802%2900049-5

7 January 2021

10.1016/S1386-6532(02)00049-5

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12367644